クローニングおよび変異導入市場- 世界の産業規模、シェア、動向、機会、予測、遺伝子タイプ別、製品タイプ別、技術別、用途別、エンドユーザー別、地域別、競合別、2020-2030年

世界のクローニングおよび変異導入市場は、2024年には26億7,000万米ドルと評価され、2030年には75億8,000万米ドルに達し、CAGR 18.99％で成長すると予測されています。

この市場は、遺伝子研究や生殖研究などの分野でクローン技術の応用が拡大していることが大きな要因となって急成長を遂げています。クローニングや変異導入キットを含む製品発売の増加や、治療開発のための幹細胞研究に対する政府投資の増加が、需要をさらに押し上げています。加えて、慢性疾患や代謝性疾患に罹患しやすい高齢化人口の世界の増加は、市場拡大に大きく寄与すると予想されます。遺伝子治療の利点や早期診断ツールに対する意識の高まりと、慢性疾患管理に対するヘルスケア支出の増加も、市場の成長軌道を支えています。さらに、頭頸部がんのような疾病の世界の負担は、高度な治療ソリューションのための遺伝子工学ツールに対する需要を引き続き促進しています。

市場促進要因

バイオテクノロジーと医薬品における遺伝子組み換え製品に対する需要の高まり

主な市場課題

遺伝子操作に関する倫理的・規制的懸念

主要市場動向

遺伝子操作ワークフローにおける人工知能の統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のクローニングおよび変異導入市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 遺伝子タイプ別（標準、複合）
  • 製品タイプ別（クローニングキット、変異導入キット）
  • 技術別（Topo PCRクローニング、平滑末端クローニング、シームレスクローニング、部位特異的変異誘発、その他）
  • 用途別（遺伝子合成、遺伝子発現、遺伝子治療、ワクチン調査、その他）
  • エンドユーザー別（製薬・バイオテクノロジー企業、学術・調査機関、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 遺伝子型別
  • 製品タイプ別
  • 技術別
  • 用途別
  • エンドユーザー別
  • 地域別

第6章 北米のクローニングおよび変異導入市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のクローニングおよび変異導入市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のクローニングおよび変異導入市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のクローニングおよび変異導入市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのクローニングおよび変異導入市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界のクローニングおよび変異導入市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威/サービス

第15章 競合情勢

• Agilent Technologies, Inc.
• Eurofins Scientific SE
• Sartorius AG
• Collecta, Inc.
• Codex DNA Inc.
• Lonza Group AG
• Charles River Laboratories International, Inc.
• TransGene Biotech Co. Ltd.
• Takara Bio, Inc.
• Thermo Fisher Scientific Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Cloning & Mutagenesis Market was valued at USD 2.67 billion in 2024 and is anticipated to reach USD 7.58 billion by 2030, growing at a CAGR of 18.99%. This market is witnessing rapid growth, largely fueled by expanding applications of cloning techniques in fields such as genetic and reproductive research. The increasing number of product launches involving cloning and mutagenesis kits, along with rising governmental investment in stem cell research for therapeutic development, is further driving demand. Additionally, the global rise in the aging population-more susceptible to chronic illnesses and metabolic disorders-is expected to significantly contribute to market expansion. Heightened awareness of gene therapy benefits and early diagnostic tools, combined with increased healthcare spending on chronic disease management, also supports the market's growth trajectory. Moreover, the global burden of diseases like head and neck cancer continues to drive demand for genetic engineering tools for advanced treatment solutions.

Key Market Drivers

Rising Demand for Genetically Engineered Products in Biotechnology and Pharmaceuticals

The global demand for genetically engineered products is one of the major growth catalysts for the cloning and mutagenesis market. These technologies are vital in developing new drugs, gene therapies, vaccines, and synthetic biological products. Cloning and mutagenesis techniques allow scientists to manipulate genes for desired traits, making them indispensable in genetic research and biopharmaceutical manufacturing. Significant public investments reinforce this trend-for instance, the U.S. Department of Health and Human Services allocated over $2.5 billion to BARDA in 2023 to support advanced vaccine and therapeutic development, much of which relies on gene manipulation techniques. Similarly, under its Horizon Europe framework, the European Commission has earmarked over €1 billion for health innovation, focusing on gene-based solutions and personalized medicine.

Key Market Challenges

Ethical and Regulatory Concerns Around Genetic Manipulation

The ethical and regulatory landscape surrounding genetic engineering poses a major challenge for the cloning and mutagenesis market. Concerns about biosafety, environmental impact, and moral implications, especially in human applications like germline editing and embryonic cloning, have led to global scrutiny. While somatic cell gene editing is generally accepted, public and institutional opposition to germline modifications persists. Following incidents like the unauthorized editing of human embryos in 2018, regulatory bodies such as the WHO and UNESCO have called for stricter oversight. Regulatory inconsistencies between regions further complicate the market-while agencies like the FDA and EMA allow controlled gene therapy, other countries enforce bans on certain genetic techniques. The EU, for example, imposes rigorous regulations on GMOs, often delaying their approval. These regulatory and ethical hurdles not only slow innovation but also increase compliance costs, especially for companies operating in sensitive sectors like human therapeutics and agricultural biotechnology.

Key Market Trends

Integration of Artificial Intelligence in Genetic Engineering Workflows

The adoption of artificial intelligence in genetic research is a transformative trend in the cloning and mutagenesis market. AI and machine learning technologies are being increasingly utilized to automate gene synthesis, select optimal mutagenesis sites, design primers, and predict protein behavior after mutation. These tools help researchers conduct high-precision experiments more efficiently and cost-effectively. AI-driven analysis of large genomic datasets enables faster identification of gene targets and potential phenotypic outcomes, streamlining drug development and genetic research. Government support is also fostering this integration. For instance, the U.S. has prioritized AI in healthcare through the National Artificial Intelligence Initiative Act and allocated over $1.5 billion for related research in 2023. Similarly, Europe's Horizon Europe program promotes AI-based innovation in biotechnology. As AI systems become more advanced and widely adopted, their impact on genetic engineering is expected to enhance the reproducibility, speed, and accuracy of cloning and mutagenesis experiments across the pharmaceutical, agricultural, and research sectors.

Key Market Players

• Agilent Technologies, Inc.
• Eurofins Scientific SE
• Sartorius AG
• Collecta, Inc.
• Codex DNA Inc.
• Lonza Group AG
• Charles River Laboratories International, Inc.
• TransGene Biotech Co. Ltd.
• Takara Bio, Inc.
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Cloning & Mutagenesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cloning & Mutagenesis Market, By Gene Type:

• Standard
• Complex

Cloning & Mutagenesis Market, By Product Type:

• Cloning Kits
• Mutagenesis Kits

Cloning & Mutagenesis Market, By Technique:

• Topo PCR Cloning
• Blunt End Cloning
• Seamless Cloning
• Site-Directed Mutagenesis

Cloning & Mutagenesis Market, By Application:

• Gene Synthesis
• Gene Expression
• Gene Therapy
• Vaccine Research
• Others

Cloning & Mutagenesis Market, By End User:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• Others

Cloning & Mutagenesis Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cloning & Mutagenesis Market.

Available Customizations:

Global Cloning & Mutagenesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cloning & Mutagenesis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Gene Type (Standard, Complex)
  • 5.2.2. By Product Type (Cloning Kits, Mutagenesis Kits)
  • 5.2.3. By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others)
  • 5.2.4. By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others)
  • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Gene Type
  • 5.3.2. By Product Type
  • 5.3.3. By Technique
  • 5.3.4. By Application
  • 5.3.5. By End User
  • 5.3.6. By Region

6. North America Cloning & Mutagenesis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Gene Type
  • 6.2.2. By Product Type
  • 6.2.3. By Technique
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cloning & Mutagenesis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Gene Type
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By Technique
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Cloning & Mutagenesis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Gene Type
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By Technique
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Cloning & Mutagenesis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Gene Type
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By Technique
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Cloning & Mutagenesis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Gene Type
  • 7.2.2. By Product Type
  • 7.2.3. By Technique
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cloning & Mutagenesis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Gene Type
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Technique
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. Germany Cloning & Mutagenesis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Gene Type
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Technique
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Cloning & Mutagenesis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Gene Type
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Technique
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Cloning & Mutagenesis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Gene Type
      • 7.3.4.2.2. By Product Type
      • 7.3.4.2.3. By Technique
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Cloning & Mutagenesis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Gene Type
      • 7.3.5.2.2. By Product Type
      • 7.3.5.2.3. By Technique
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia-Pacific Cloning & Mutagenesis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Gene Type
  • 8.2.2. By Product Type
  • 8.2.3. By Technique
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cloning & Mutagenesis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Gene Type
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Technique
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Cloning & Mutagenesis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Gene Type
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Technique
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Cloning & Mutagenesis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Gene Type
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Technique
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Cloning & Mutagenesis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Gene Type
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By Technique
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Cloning & Mutagenesis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Gene Type
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By Technique
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. South America Cloning & Mutagenesis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Gene Type
  • 9.2.2. By Product Type
  • 9.2.3. By Technique
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cloning & Mutagenesis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Gene Type
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Technique
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Cloning & Mutagenesis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Gene Type
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By Technique
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Cloning & Mutagenesis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Gene Type
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Technique
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. Middle East and Africa Cloning & Mutagenesis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Gene Type
  • 10.2.2. By Product Type
  • 10.2.3. By Technique
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cloning & Mutagenesis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Gene Type
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By Technique
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Cloning & Mutagenesis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Gene Type
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By Technique
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. UAE Cloning & Mutagenesis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Gene Type
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By Technique
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Cloning & Mutagenesis Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Eurofins Scientific SE
• 15.3. Sartorius AG
• 15.4. Collecta, Inc.
• 15.5. Codex DNA Inc.
• 15.6. Lonza Group AG
• 15.7. Charles River Laboratories International, Inc.
• 15.8. TransGene Biotech Co. Ltd.
• 15.9. Takara Bio, Inc.
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer